TY - JOUR
T1 - Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw
T2 - A prospective feasibility study
AU - Kim, Jin Woo
AU - Kim, Sun Jong
AU - Kim, Myung Rae
N1 - Funding Information:
This study was supported by the Ewha Global Top5 Grant 2013 of the Ewha Womans University, Seoul, Korea. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.
Publisher Copyright:
© 2014 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Our aim was to assess the feasibility of using leucocyte-rich and platelet-rich fibrin (L-PRF) for the treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in a single group study. After treatment with L-PRF, the response of each patient was recorded 1 month and 4 months postoperatively. Further assessments were made of the site, stage, concentration of c-terminal crosslinked telopepide of type 1 collagen, and actinomycosis. Among the total of 34 patients, 26 (77%) showed complete resolution, 6 (18%) had delayed resolution, and 2 (6%) showed no resolution. There was a significant association between the response to treatment and the stage of BRONJ (p = 0.002) but no other significant associations were detected. This study has shown that it is feasible to use L-PRF for the treatment of BRONJ, but the effectiveness cannot be judged with this study design. Randomised prospective trials are needed to confirm this.
AB - Our aim was to assess the feasibility of using leucocyte-rich and platelet-rich fibrin (L-PRF) for the treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in a single group study. After treatment with L-PRF, the response of each patient was recorded 1 month and 4 months postoperatively. Further assessments were made of the site, stage, concentration of c-terminal crosslinked telopepide of type 1 collagen, and actinomycosis. Among the total of 34 patients, 26 (77%) showed complete resolution, 6 (18%) had delayed resolution, and 2 (6%) showed no resolution. There was a significant association between the response to treatment and the stage of BRONJ (p = 0.002) but no other significant associations were detected. This study has shown that it is feasible to use L-PRF for the treatment of BRONJ, but the effectiveness cannot be judged with this study design. Randomised prospective trials are needed to confirm this.
KW - Bisphosphonate
KW - Growth factor
KW - Osteonecrosis of the jaw
KW - Platelet concentrate
KW - Platelet-rich fibrin
UR - http://www.scopus.com/inward/record.url?scp=84908227739&partnerID=8YFLogxK
U2 - 10.1016/j.bjoms.2014.07.256
DO - 10.1016/j.bjoms.2014.07.256
M3 - Article
C2 - 25138613
AN - SCOPUS:84908227739
SN - 0266-4356
VL - 52
SP - 854
EP - 859
JO - British Journal of Oral and Maxillofacial Surgery
JF - British Journal of Oral and Maxillofacial Surgery
IS - 9
ER -